Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 13%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Liquidia is a biopharmaceutical company with a strong pipeline and a unique particle engineering platform technology that sets it apart from its competitors. With a promising drug in the market and ongoing studies for other indications, the company is well-positioned for future growth and has a strong likelihood of success. Although there are some risks, such as potential competition and the need for additional financing, the company's solid financial standing and strong management team make it a solid investment opportunity.

Bears say

Liquidia is in a promising market position as it continues to develop and commercialize products for the treatment of pulmonary hypertension (PH) and other related diseases. However, while its lead candidate Yutrepia has the potential to be a blockbuster drug, there is still a lack of penetration in this market, and competition from other innovative treatments could limit its growth potential. Additionally, the uncertainty surrounding patent infringement lawsuits and the potential for monetary penalties or injunctions could pose risks to the company's financials. Overall, while Liquidia has potential for growth, there are significant uncertainties and challenges that could impact its stock performance.

LQDA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 8 analysts, LQDA has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.